| 1 | Application of unified health large language model evaluation framework to In-Basket message replies: bridging qualitative and quantitative assessments | 3.5 | 8 | Citations (PDF) |
| 2 | Exploring trade-offs in equitable stroke risk prediction with parity-constrained and race-free models | 5.7 | 2 | Citations (PDF) |
| 3 | Algorithm-Based Clinical Decision Support: Evolving Regulatory Landscape and Best Practices for Local Oversight | 4.9 | 3 | Citations (PDF) |
| 4 | ApoB and Lp(a): core measures to assess cardiovascular risk | 2.2 | 5 | Citations (PDF) |
| 5 | ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk | 3.1 | 14 | Citations (PDF) |
| 6 | Letter by Rich-Edwards et al Regarding Article, “Assessing the Accuracy of Cardiovascular Disease Prediction Using Female-Specific Risk Factors in Women Aged 45 to 69 Years in the UK Biobank Study” | 4.1 | 1 | Citations (PDF) |
| 7 | Trans-Balance: Reducing demographic disparity for prediction models in the presence of class imbalance | 3.7 | 10 | Citations (PDF) |
| 8 | A Nationwide Network of Health AI Assurance Laboratories | 16.5 | 102 | Citations (PDF) |
| 9 | The Causal-Benefit Model to Prevent Cardiovascular Events | 1.3 | 16 | Citations (PDF) |
| 10 | Discordance among apoB, non–high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention | 2.2 | 93 | Citations (PDF) |
| 11 | The Crucial Role of Academic Medical Centers in Preparing for the Future of Health AI | 0.1 | 0 | Citations (PDF) |
| 12 | Discordance Analysis of VLDL-C and ApoB in UK Biobank and Framingham Study: A Prospective Observational Study | 6.0 | 13 | Citations (PDF) |
| 13 | Hemoglobin A1c and abdominal obesity as predictors of diabetes and ASCVD in individuals with prediabetes in UK Biobank: a prospective observational study | 9.4 | 6 | Citations (PDF) |
| 14 | Calibration and Uncertainty in Neural Time-to-Event Modeling | 10.1 | 11 | Citations (PDF) |
| 15 | Interplay of Atherogenic Particle Number and Particle Size and the Risk of Coronary Heart Disease | 1.1 | 4 | Citations (PDF) |
| 16 | Cardiovascular Disease Risk Prediction in Young Adults—The Next Frontier | 11.1 | 3 | Citations (PDF) |
| 17 | Is hypertriglyceridemia a reliable indicator of cholesterol-depleted Apo B particles? | 3.1 | 12 | Citations (PDF) |
| 18 | Semi-supervised calibration of noisy event risk (SCANER) with electronic health records | 3.7 | 3 | Citations (PDF) |
| 19 | Concordance/discordance between serum apolipoprotein B, low density lipoprotein cholesterol and non-high density lipoprotein cholesterol in NATPOL 2011 participants – An epidemiological perspective | 2.2 | 12 | Citations (PDF) |
| 20 | External validation of AI models in health should be replaced with recurring local validation | 33.0 | 143 | Citations (PDF) |
| 21 | Antiarrhythmic effect of 9-week hybrid comprehensive telerehabilitation and its influence on cardiovascular mortality in long-term follow-up – subanalysis of the TELEREHabilitation in Heart Failure Patients randomized clinical trial | 1.1 | 3 | Citations (PDF) |
| 22 | Observability and its impact on differential bias for clinical prediction models | 3.5 | 13 | Citations (PDF) |
| 23 | Prognostic Impact of Hybrid Comprehensive Telerehabilitation Regarding Diastolic Dysfunction in Patients with Heart Failure with Reduced Ejection Fraction—Subanalysis of the TELEREH-HF Randomized Clinical Trial | 2.5 | 3 | Citations (PDF) |
| 24 | A proposal for developing a platform that evaluates algorithmic equity and accuracy | 3.0 | 33 | Citations (PDF) |
| 25 | An adverse lipoprotein phenotype—hypertriglyceridaemic hyperapolipoprotein B—and the long-term risk of type 2 diabetes: a prospective, longitudinal, observational cohort study | 10.3 | 8 | Citations (PDF) |
| 26 | A framework for the oversight and local deployment of safe and high-quality prediction models | 3.5 | 104 | Citations (PDF) |
| 27 | Clinical Trials in the 21st Century — Promising Avenues for Better Studies | 10.0 | 6 | Citations (PDF) |
| 28 | Predictive Utility of a Validated Polygenic Risk Score for Long-Term Risk of Coronary Heart Disease in Young and Middle-Aged Adults | 18.0 | 27 | Citations (PDF) |
| 29 | Impact of the COVID-19 pandemic on patterns of outpatient cardiovascular care | 2.9 | 91 | Citations (PDF) |
| 30 | The Dose–Response Relationship Between Physical Activity and Cardiometabolic Health in Adolescents | 3.2 | 36 | Citations (PDF) |
| 31 | An Aetiology-Based Subanalysis of the Telerehabilitation in Heart Failure Patients (TELEREH-HF) Trial | 3.1 | 14 | Citations (PDF) |
| 32 | Effects of hybrid comprehensive telerehabilitation on cardiopulmonary capacity in heart failure patients depending on diabetes mellitus: subanalysis of the TELEREH-HF randomized clinical trial | 9.4 | 19 | Citations (PDF) |
| 33 | Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | 34.5 | 275 | Citations (PDF) |
| 34 | Impact of train/test sample regimen on performance estimate stability of machine learning in cardiovascular imaging | 3.4 | 85 | Citations (PDF) |
| 35 | Assessment of ECG during hybrid comprehensive telerehabilitation in heart failure patients—Subanalysis of the Telerehabilitation in Heart Failure Patients (TELEREH‐HF) randomized clinical trial | 1.0 | 10 | Citations (PDF) |
| 36 | Using Propensity Score Methods to Create Target Populations in Observational Clinical Research | 16.5 | 171 | Citations (PDF) |
| 37 | Effects of a 9-Week Hybrid Comprehensive Telerehabilitation Program on Long-term Outcomes in Patients With Heart Failure | 11.1 | 171 | Citations (PDF) |
| 38 | Remote Monitoring of Cardiac Implantable Electronic Devices in Patients Undergoing Hybrid Comprehensive Telerehabilitation in Comparison to the Usual Care. Subanalysis from Telerehabilitation in Heart Failure Patients (TELEREH-HF) Randomised Clinical Trial | 2.5 | 12 | Citations (PDF) |
| 39 | The Expected 30-Year Benefits of Early Versus Delayed Primary Prevention of Cardiovascular Disease by Lipid Lowering | 18.0 | 78 | Citations (PDF) |
| 40 | Overlap Weighting | 16.5 | 715 | Citations (PDF) |
| 41 | The Dose–Response Relationship Between Physical Activity and Cardiometabolic Health in Young Adults | 2.7 | 21 | Citations (PDF) |
| 42 | Prevention of cardiovascular disease: time for a course correction | 2.2 | 4 | Citations (PDF) |
| 43 | Application of net reclassification index to non-nested and point-based risk prediction models: a review | 2.2 | 54 | Citations (PDF) |
| 44 | Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke | 17.6 | 86 | Citations (PDF) |
| 45 | Trajectories of Non–HDL Cholesterol Across Midlife | 2.3 | 95 | Citations (PDF) |
| 46 | Apolipoprotein B Particles and Cardiovascular Disease | 11.1 | 523 | Citations (PDF) |
| 47 | Cost-effectiveness of Low-density Lipoprotein Cholesterol Level–Guided Statin Treatment in Patients With Borderline Cardiovascular Risk | 11.1 | 43 | Citations (PDF) |
| 48 | Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials | 2.9 | 14 | Citations (PDF) |
| 49 | Statistical methods for building better biomarkers of chronic kidney disease | 1.7 | 10 | Citations (PDF) |
| 50 | Measures for evaluation of prognostic improvement under multivariate normality for nested and nonnested models | 1.7 | 7 | Citations (PDF) |
| 51 | Egg Consumption and Risk of Total and Cause-Specific Mortality: An Individual-Based Cohort Study and Pooling Prospective Studies on Behalf of the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group | 2.7 | 33 | Citations (PDF) |
| 52 | An outcome model approach to transporting a randomized controlled trial results to a target population | 3.5 | 11 | Citations (PDF) |
| 53 | Cardiovascular risk factor profiles in familial hypercholesterolemia patients with and without genetic mutation compared to a nationally representative sample of adults in a high-risk European country | 2.9 | 1 | Citations (PDF) |
| 54 | Quantifying Importance of Major Risk Factors for Coronary Heart Disease | 18.0 | 212 | Citations (PDF) |
| 55 | Improving patient risk communication: Translating cardiovascular risk into standardized risk percentiles | 2.9 | 23 | Citations (PDF) |
| 56 | Nonparametric estimation and inference for polytomous discrimination index | 1.6 | 16 | Citations (PDF) |
| 57 | Longitudinal FGF23 Trajectories and Mortality in Patients with CKD | 0.4 | 132 | Citations (PDF) |
| 58 | A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention | 11.1 | 37 | Citations (PDF) |
| 59 | Microsimulation model to predict incremental value of biomarkers added to prognostic models | 3.5 | 2 | Citations (PDF) |
| 60 | Sick Individuals and Sick Populations by Geoffrey Rose: Cardiovascular Prevention Updated | 4.0 | 21 | Citations (PDF) |
| 61 | On Deep Learning for Medical Image Analysis | 16.5 | 89 | Citations (PDF) |
| 62 | High-sensitivity C-reactive protein elevation in patients with prior myocardial infarction in the United States | 2.9 | 13 | Citations (PDF) |
| 63 | Placebo Response as a Latent Characteristic: Application to Analysis of Sequential Parallel Comparison Design Studies | 3.4 | 6 | Citations (PDF) |
| 64 | Opportunities and challenges in developing risk prediction models with electronic health records data: a systematic review | 3.5 | 821 | Citations (PDF) |
| 65 | Predicting mortality over different time horizons: which data elements are needed? | 3.5 | 28 | Citations (PDF) |
| 66 | Low-density lipoprotein cholesterol and survival in pulmonary arterial hypertension | 3.4 | 33 | Citations (PDF) |
| 67 | Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines | 16.5 | 53 | Citations (PDF) |
| 68 | Data monitoring committees: Promoting best practices to address emerging challenges | 1.8 | 83 | Citations (PDF) |
| 69 | Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation | 16.5 | 218 | Citations (PDF) |
| 70 | Combining clinical and angiographic variables for estimating risk of target lesion revascularization after drug eluting stent placement | 0.7 | 9 | Citations (PDF) |
| 71 | Transcatheter Versus Surgical Aortic Valve Replacement | 2.3 | 90 | Citations (PDF) |
| 72 | Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease | 18.0 | 3 | Citations (PDF) |
| 73 | Asymptotic distribution of ∆AUC, NRIs, and IDI based on theory of U‐statistics | 1.7 | 27 | Citations (PDF) |
| 74 | Multi-category diagnostic accuracy based on logistic regression | 1.4 | 9 | Citations (PDF) |
| 75 | Scientific, societal, and economic consequences of releasing interim data from clinical trials | 3.7 | 1 | Citations (PDF) |
| 76 | Population Effect of Differences in Cholesterol Guidelines in Eastern Europe and the United States | 11.1 | 14 | Citations (PDF) |
| 77 | Estimation of Risk for Initial Atherosclerotic Cardiovascular Disease Events | 18.0 | 1 | Citations (PDF) |
| 78 | A comparison of time dependent Cox regression, pooled logistic regression and cross sectional pooling with simulations and an application to the Framingham Heart Study | 2.5 | 78 | Citations (PDF) |
| 79 | Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus | 11.1 | 213 | Citations (PDF) |
| 80 | Statin Utilization and Recommendations Among HIV- and HCV-infected Veterans: A Cohort Study | 5.2 | 59 | Citations (PDF) |
| 81 | Assessing Cardiovascular Risk to Guide Hypertension Diagnosis and Treatment | 11.1 | 32 | Citations (PDF) |
| 82 | Do Not Over (P) Value Your Research Article | 11.1 | 30 | Citations (PDF) |
| 83 | Electronic Health Records and Pharmacokinetic Modeling to Assess the Relationship between Ampicillin Exposure and Seizure Risk in Neonates | 2.0 | 33 | Citations (PDF) |
| 84 | Determining When to Add Nonstatin Therapy | 2.3 | 130 | Citations (PDF) |
| 85 | Controlling for Informed Presence Bias Due to the Number of Health Encounters in an Electronic Health Record | 3.3 | 154 | Citations (PDF) |
| 86 | Temporal Changes in the Association Between Modifiable Risk Factors and Coronary Heart Disease Incidence | 16.5 | 33 | Citations (PDF) |
| 87 | Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low‐Density Lipoprotein Cholesterol or Non‐High‐Density Lipoprotein Cholesterol | 4.0 | 60 | Citations (PDF) |
| 88 | A calibration hierarchy for risk models was defined: from utopia to empirical data | 3.7 | 739 | Citations (PDF) |
| 89 | Risk of Premature Cardiovascular Disease vs the Number of Premature Cardiovascular Events | 11.1 | 69 | Citations (PDF) |
| 90 | Choice of agreement indices for assessing and improving measurement reproducibility in a core laboratory setting | 1.6 | 57 | Citations (PDF) |
| 91 | Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial | 2.9 | 99 | Citations (PDF) |
| 92 | Use of Open Access Platforms for Clinical Trial Data | 16.5 | 63 | Citations (PDF) |
| 93 | Supporting open access to clinical trial data for researchers: The Duke Clinical Research Institute–Bristol-Myers Squibb Supporting Open Access to Researchers Initiative | 2.9 | 29 | Citations (PDF) |
| 94 | Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease | 18.0 | 84 | Citations (PDF) |
| 95 | RE: Net Risk Reclassification P Values: Valid or Misleading? | 4.6 | 8 | Citations (PDF) |
| 96 | Calibration and Discrimination Among Multiple Cardiovascular Risk Scores in a Modern Multiethnic Cohort | 9.6 | 4 | Citations (PDF) |
| 97 | On the quantitative assessment of predictive biomarkers | 4.6 | 9 | Citations (PDF) |
| 98 | Limitations in the conventional assessment of the incremental value of predictors of cardiovascular risk | 4.0 | 12 | Citations (PDF) |
| 99 | Graphical assessment of incremental value of novel markers in prediction models: From statistical to decision analytical perspectives | 1.2 | 25 | Citations (PDF) |
| 100 | Response to Letter Regarding Article, “Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease” | 18.0 | 3 | Citations (PDF) |
| 101 | Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C | 2.0 | 152 | Citations (PDF) |
| 102 | Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease | 18.0 | 358 | Citations (PDF) |
| 103 | Clinical Effectiveness of Statin Therapy After Ischemic Stroke: Primary Results From the Statin Therapeutic Area of the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study | 18.0 | 50 | Citations (PDF) |
| 104 | Using Age- and Sex-Specific Risk Thresholds to Guide Statin Therapy | 2.3 | 72 | Citations (PDF) |
| 105 | Substance use and mental diagnoses among adults with and without type 2 diabetes: Results from electronic health records data | 2.9 | 57 | Citations (PDF) |
| 106 | Applicability and potential clinical effects of 2013 cholesterol guidelines on major cardiovascular events | 2.9 | 7 | Citations (PDF) |
| 107 | Inference for reclassification statistics under nested and non-nested models for biomarker evaluation | 1.9 | 11 | Citations (PDF) |
| 108 | Evaluating Discrimination of Risk Prediction Models | 16.5 | 359 | Citations (PDF) |
| 109 | P-wave indices and atrial fibrillation: Cross-cohort assessments from the Framingham Heart Study (FHS) and Atherosclerosis Risk in Communities (ARIC) study | 2.9 | 99 | Citations (PDF) |
| 110 | Serial Measurements of N-Terminal Pro-Brain Natriuretic Peptide in Patients with Coronary Heart Disease | 2.3 | 11 | Citations (PDF) |
| 111 | Admission Cell Free DNA Levels Predict 28-Day Mortality in Patients with Severe Sepsis in Intensive Care | 2.3 | 80 | Citations (PDF) |
| 112 | Application of the New Cholesterol Guidelines | 34.5 | 6 | Citations (PDF) |
| 113 | Proportion of US Adults Potentially Affected by the 2014 Hypertension Guideline | 16.5 | 96 | Citations (PDF) |
| 114 | Sensitivity and Specificity Can Change in Opposite Directions When New Predictive Markers Are Added to Risk Models | 2.2 | 9 | Citations (PDF) |
| 115 | Risk Assessment to Predict Arterial and Venous Events in Patients Undergoing Percutaneous Coronary Intervention | 1.7 | 2 | Citations (PDF) |
| 116 | Application of New Cholesterol Guidelines to a Population-Based Sample | 34.5 | 598 | Citations (PDF) |
| 117 | Clinical Implications of Chronic Heart Failure Phenotypes Defined by Cluster Analysis | 2.3 | 233 | Citations (PDF) |
| 118 | Taking a longer term view of cardiovascular risk: the causal exposure paradigm | 0.2 | 28 | Citations (PDF) |
| 119 | Heparin Monotherapy or Bivalirudin During Percutaneous Coronary Intervention in Patients With Non–ST-Segment–Elevation Acute Coronary Syndromes or Stable Ischemic Heart Disease | 4.8 | 14 | Citations (PDF) |
| 120 | Quantifying Cardiometabolic Risk Using Modifiable Non–Self-Reported Risk Factors | 3.2 | 13 | Citations (PDF) |
| 121 | The Knowledge and Awareness of Hypertension Among Patients With Hypertension in Central Poland | 1.9 | 10 | Citations (PDF) |
| 122 | Left Ventricular Hypertrophy Patterns and Incidence of Heart Failure With Preserved Versus Reduced Ejection Fraction | 1.8 | 126 | Citations (PDF) |
| 123 | Influence of exercise training on T-wave alternans assessed during exercise test in heart failure patients | 2.2 | 5 | Citations (PDF) |
| 124 | Charting a Roadmap for Heart Failure Biomarker Studies | 4.4 | 84 | Citations (PDF) |
| 125 | Model for End-Stage Liver Disease score predicts mortality in critically ill cirrhotic patients | 2.3 | 27 | Citations (PDF) |
| 126 | What to expect from net reclassification improvement with three categories | 1.7 | 21 | Citations (PDF) |
| 127 | Predicted Long-Term Cardiovascular Risk Among Young Adults in the National Longitudinal Study of Adolescent Health | 2.8 | 61 | Citations (PDF) |
| 128 | Association of Smoking Cessation and Weight Change With Cardiovascular Disease Among Adults With and Without Diabetes | 16.5 | 236 | Citations (PDF) |
| 129 | Prognostic implications of procedural vs spontaneous myocardial infarction: Results from the Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) registry | 2.9 | 35 | Citations (PDF) |
| 130 | Impact of correlation on predictive ability of biomarkers | 1.7 | 18 | Citations (PDF) |
| 131 | The effects of statins on blood pressure in normotensive or hypertensive subjects — A meta-analysis of randomized controlled trials | 2.2 | 38 | Citations (PDF) |
| 132 | Risk Assessment for Incident Heart Failure in Individuals With Atrial Fibrillation | 7.3 | 120 | Citations (PDF) |
| 133 | Comparison of Operating Characteristics of Commonly Used Sample Size Re-Estimation Procedures in a Two-Stage Design | 1.3 | 2 | Citations (PDF) |
| 134 | Risk of type 2 diabetes and cumulative excess weight exposure in the Framingham Offspring Study | 2.4 | 15 | Citations (PDF) |
| 135 | The PARACHUTE IV trial design and rationale: Percutaneous ventricular restoration using the parachute device in patients with ischemic heart failure and dilated left ventricles | 2.9 | 59 | Citations (PDF) |
| 136 | Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy—A meta-analysis of 11 randomized controlled trials involving 21,295 participants | 9.1 | 96 | Citations (PDF) |
| 137 | Genetic Predisposition to Higher Blood Pressure Increases Coronary Artery Disease Risk | 6.6 | 74 | Citations (PDF) |
| 138 | Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials | 2.1 | 38 | Citations (PDF) |
| 139 | Simple Risk Model Predicts Incidence of Atrial Fibrillation in a Racially and Geographically Diverse Population: the CHARGE‐AF Consortium | 4.0 | 814 | Citations (PDF) |
| 140 | Repeat Bone Mineral Density Screening and Prediction of Hip and Major Osteoporotic Fracture | 16.5 | 73 | Citations (PDF) |
| 141 | Neck Circumference and the Development of Cardiovascular Disease Risk Factors in the Framingham Heart Study | 6.2 | 60 | Citations (PDF) |
| 142 | Atrial Fibrillation Patterns and Risks of Subsequent Stroke, Heart Failure, or Death in the Community | 4.0 | 72 | Citations (PDF) |
| 143 | Sex‐Specific Differences in the Predictive Value of Cholesterol Homeostasis Markers and 10‐Year Cardiovascular Disease Event Rate in Framingham Offspring Study Participants | 4.0 | 54 | Citations (PDF) |
| 144 | Validation of a Breast Cancer Risk Prediction Model Developed for Black Women | 4.6 | 14 | Citations (PDF) |
| 145 | The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression | 1.2 | 8 | Citations (PDF) |
| 146 | Age Trends in Estradiol and Estrone Levels Measured Using Liquid Chromatography Tandem Mass Spectrometry in Community-Dwelling Men of the Framingham Heart Study | 3.4 | 89 | Citations (PDF) |
| 147 | Incremental value of rare genetic variants for the prediction of multifactorial diseases | 9.6 | 10 | Citations (PDF) |
| 148 | Evaluation of Markers and Risk Prediction Models | 2.2 | 75 | Citations (PDF) |
| 149 | Early-Adulthood Cardiovascular Disease Risk Factor Profiles Among Individuals With and Without Diabetes in the Framingham Heart Study | 6.2 | 25 | Citations (PDF) |
| 150 | Lack of interaction of beta-cell-function-associated variants with hypertension on change in fasting glucose and diabetes risk | 2.1 | 1 | Citations (PDF) |
| 151 | Cardiovascular Disease Risk Assessment: Insights from Framingham | 2.5 | 279 | Citations (PDF) |
| 152 | Troponin Criteria for Myocardial Infarction After Percutaneous Coronary Intervention | 8.1 | 102 | Citations (PDF) |
| 153 | Repeat Revascularization After Contemporary Percutaneous Coronary Intervention | 4.8 | 73 | Citations (PDF) |
| 154 | Invited Commentary: Clinical Usefulness of the Framingham Cardiovascular Risk Profile Beyond Its Statistical Performance | 3.3 | 11 | Citations (PDF) |
| 155 | Comparison of Academic and Nonacademic Sites in Multi-Center Clinical Trials | 1.7 | 6 | Citations (PDF) |
| 156 | Genotype Prediction of Adult Type 2 Diabetes From Adolescence in a Multiracial Population | 4.5 | 42 | Citations (PDF) |
| 157 | Interpreting Incremental Value of Markers Added to Risk Prediction Models | 3.3 | 454 | Citations (PDF) |
| 158 | Evaluating Treatment Efficacy by Multiple End Points in Phase II Acute Heart Failure Clinical Trials | 4.4 | 50 | Citations (PDF) |
| 159 | Coronary Computed Tomographic Angiography and Risk of All-Cause Mortality and Nonfatal Myocardial Infarction in Subjects Without Chest Pain Syndrome From the CONFIRM Registry (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry) | 18.0 | 223 | Citations (PDF) |
| 160 | Pencina et al. Respond to "The Incremental Value of New Markers" and "Clinically Relevant Measures? A Note of Caution" | 3.3 | 5 | Citations (PDF) |
| 161 | Caution Is Needed in the Interpretation of Added Value of Biomarkers Analyzed in Matched Case Control Studies | 1.1 | 8 | Citations (PDF) |
| 162 | Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome | 2.2 | 100 | Citations (PDF) |
| 163 | Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community | 2.2 | 146 | Citations (PDF) |
| 164 | Ankle–brachial index and cardiovascular risk prediction: An analysis of 11,594 individuals with 10-year follow-up | 1.5 | 63 | Citations (PDF) |
| 165 | A genetic risk score based on direct associations with coronary heart disease improves coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC), but not in the Rotterdam and Framingham Offspring, Studies | 1.5 | 71 | Citations (PDF) |
| 166 | Variations in Common Carotid Artery Intima-Media Thickness during the Cardiac Cycle: Implications for Cardiovascular Risk Assessment | 3.4 | 36 | Citations (PDF) |
| 167 | An International Model to Predict Recurrent Cardiovascular Disease | 2.0 | 211 | Citations (PDF) |
| 168 | Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community | 2.3 | 565 | Citations (PDF) |
| 169 | A Genetic Risk Score Is Associated With Incident Cardiovascular Disease and Coronary Artery Calcium | 3.8 | 207 | Citations (PDF) |
| 170 | Novel metrics for evaluating improvement in discrimination: net reclassification and integrated discrimination improvement for normal variables and nested models | 1.7 | 310 | Citations (PDF) |
| 171 | Quantifying discrimination of Framingham risk functions with different survival C statistics | 1.7 | 84 | Citations (PDF) |
| 172 | Misuse of DeLong test to compare AUCs for nested models | 1.7 | 272 | Citations (PDF) |
| 173 | Assessing the incremental value of diagnostic and prognostic markers: a review and illustration | 3.0 | 201 | Citations (PDF) |
| 174 | Understanding increments in model performance metrics | 0.8 | 35 | Citations (PDF) |
| 175 | Red cell distribution width is a predictor of mortality in patients undergoing percutaneous coronary intervention | 1.9 | 36 | Citations (PDF) |
| 176 | Efficacy of Dose Increase Among Nonresponders to Low-Dose Aripiprazole Augmentation in Patients With Inadequate Response to Antidepressant Treatment: | 1.8 | 18 | Citations (PDF) |
| 177 | Rationale and design of the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter) Registry | 2.7 | 166 | Citations (PDF) |
| 178 | Rationale and design of the MASS COMM trial: A randomized trial to compare percutaneous coronary intervention between MASSachusetts hospitals with cardiac surgery on-site and COMMunity hospitals without cardiac surgery on-site | 2.9 | 3 | Citations (PDF) |
| 179 | Strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS): explanation and elaboration | 3.7 | 9 | Citations (PDF) |
| 180 | Segment-Specific Association Between Plasma Homocysteine Level and Carotid Artery Intima-Media Thickness in the Framingham Offspring Study | 1.6 | 24 | Citations (PDF) |
| 181 | Medidas del rendimiento de modelos de predicción y marcadores pronósticos: evaluación de las predicciones y clasificaciones | 1.1 | 59 | Citations (PDF) |
| 182 | Performance Measures for Prediction Models and Markers: Evaluation of Predictions and Classifications | 0.4 | 22 | Citations (PDF) |
| 183 | Prevalence of low ankle-brachial index, elevated plasma fibrinogen and CRP across Framingham risk categories: Data from the National Health and Nutrition Examination Survey (NHANES) 1999–2004 | 1.5 | 14 | Citations (PDF) |
| 184 | Performance of current guidelines for coronary heart disease prevention: Optimal use of the Framingham-based risk assessment | 1.5 | 30 | Citations (PDF) |
| 185 | Circulating plasma cholesteryl ester transfer protein activity and blood pressure tracking in the community | 2.1 | 6 | Citations (PDF) |
| 186 | Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration | 3.0 | 33 | Citations (PDF) |
| 187 | Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration | 3.0 | 14 | Citations (PDF) |
| 188 | Effect of Clopidogrel Pretreatment on Ischemic Complications of Percutaneous Coronary Intervention Among Bivalirudin-Treated Patients (from the EVENT Registry) | 1.8 | 7 | Citations (PDF) |
| 189 | Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration | 5.3 | 14 | Citations (PDF) |
| 190 | Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers | 1.7 | 2,300 | Citations (PDF) |
| 191 | On the C‐statistics for evaluating overall adequacy of risk prediction procedures with censored survival data | 1.7 | 1,369 | Citations (PDF) |
| 192 | Equivalence of improvement in area under ROC curve and linear discriminant analysis coefficient under assumption of normality | 1.7 | 34 | Citations (PDF) |
| 193 | Bleeding Risk Comparing Targeted Low-Dose Heparin With Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention | 4.8 | 28 | Citations (PDF) |
| 194 | Higher aldosterone and lower N-terminal proatrial natriuretic peptide as biomarkers of salt sensitivity in the community | 2.2 | 14 | Citations (PDF) |
| 195 | Improved Cardiac Risk Assessment With Noninvasive Measures of Coronary Flow Reserve | 18.0 | 817 | Citations (PDF) |
| 196 | Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease | 16.5 | 340 | Citations (PDF) |
| 197 | Common Carotid Artery Intima-Media Thickness Progression as a Predictor of Stroke in Multi-Ethnic Study of Atherosclerosis | 5.9 | 170 | Citations (PDF) |
| 198 | Associations of Edge-Detected and Manual-Traced Common Carotid Intima-Media Thickness Measurements With Framingham Risk Factors | 5.9 | 52 | Citations (PDF) |
| 199 | Genetic Risk Reclassification for Type 2 Diabetes by Age Below or Above 50 Years Using 40 Type 2 Diabetes Risk Single Nucleotide Polymorphisms | 6.2 | 175 | Citations (PDF) |
| 200 | Clinical and Economic Outcomes of Liberal Versus Selective Drug-Eluting Stent Use | 18.0 | 41 | Citations (PDF) |
| 201 | Prognostic Implications of Creatine Kinase-MB Elevation After Percutaneous Coronary Intervention | 4.8 | 46 | Citations (PDF) |
| 202 | Carotid-Wall Intima–Media Thickness and Cardiovascular Events | 34.5 | 759 | Citations (PDF) |
| 203 | A cost-minimization analysis of dexmedetomidine compared with midazolam for long-term sedation in the intensive care unit* | 0.5 | 125 | Citations (PDF) |
| 204 | Reclassification Calculations for Persons With Incomplete Follow-up | 9.6 | 77 | Citations (PDF) |
| 205 | Cross-Sectional Relations of Lipid Concentrations to Left Ventricular Structural Attributes | 1.8 | 5 | Citations (PDF) |
| 206 | Frequency of Major Noncardiac Surgery and Subsequent Adverse Events in the Year After Drug-Eluting Stent Placement | 3.0 | 152 | Citations (PDF) |
| 207 | Routine Laboratory Results and Thirty Day and One-Year Mortality Risk Following Hospitalization with Acute Decompensated Heart Failure | 2.3 | 86 | Citations (PDF) |
| 208 | Assessing the Performance of Prediction Models | 2.8 | 4,486 | Citations (PDF) |
| 209 | Familial Aggregation of Left Ventricular Geometry and Association With Parental Heart Failure | 3.8 | 19 | Citations (PDF) |
| 210 | Iatrogenic Gastric Acid Suppression and the Risk of Nosocomial Clostridium difficile Infection | 8.1 | 397 | Citations (PDF) |
| 211 | Arterial Stiffness and Cardiovascular Events | 18.0 | 2,138 | Citations (PDF) |
| 212 | Association Between Familial Atrial Fibrillation and Risk of New-Onset Atrial Fibrillation | 16.5 | 286 | Citations (PDF) |
| 213 | Improvement of cardiovascular risk prediction: time to review current knowledge, debates, and fundamentals on how to assess test characteristics | 2.2 | 35 | Citations (PDF) |
| 214 | Diet Quality, Physical Activity, Smoking Status, and Weight Fluctuation Are Associated with Weight Change in Women and Men | 2.9 | 55 | Citations (PDF) |
| 215 | Predicting Restenosis of Drug-Eluting Stents Placed in Real-World Clinical Practice | 4.8 | 84 | Citations (PDF) |
| 216 | Relations of Biomarkers of Distinct Pathophysiological Pathways and Atrial Fibrillation Incidence in the Community | 18.0 | 273 | Citations (PDF) |
| 217 | Validation of an Atrial Fibrillation Risk Algorithm in Whites and African Americans | 8.1 | 124 | Citations (PDF) |
| 218 | Free Testosterone Levels Are Associated with Mobility Limitation and Physical Performance in Community-Dwelling Men: The Framingham Offspring Study | 4.0 | 141 | Citations (PDF) |
| 219 | Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions | 2.9 | 159 | Citations (PDF) |
| 220 | Statistical methods for assessment of added usefulness of new biomarkers | 2.3 | 309 | Citations (PDF) |
| 221 | Trends in Cardiovascular Disease Risk Factors in Individuals With and Without Diabetes Mellitus in the Framingham Heart Study | 18.0 | 241 | Citations (PDF) |
| 222 | Relations of Matrix Remodeling Biomarkers to Blood Pressure Progression and Incidence of Hypertension in the Community | 18.0 | 60 | Citations (PDF) |
| 223 | Trends in All-Cause and Cardiovascular Disease Mortality Among Women and Men With and Without Diabetes Mellitus in the Framingham Heart Study, 1950 to 2005 | 18.0 | 552 | Citations (PDF) |
| 224 | Novel and Conventional Biomarkers for Prediction of Incident Cardiovascular Events in the Community | 16.5 | 493 | Citations (PDF) |
| 225 | Alterations in cholesterol absorption/synthesis markers characterize Framingham Offspring Study participants with CHD | 3.6 | 156 | Citations (PDF) |
| 226 | Longitudinal Tracking of Left Ventricular Mass Over the Adult Life Course | 18.0 | 191 | Citations (PDF) |
| 227 | Association of Circulating Cholesteryl Ester Transfer Protein Activity With Incidence of Cardiovascular Disease in the Community | 18.0 | 126 | Citations (PDF) |
| 228 | Relation of Corneal Arcus to Cardiovascular Disease (from the Framingham Heart Study Data Set) | 1.8 | 35 | Citations (PDF) |
| 229 | Prevalence, Clinical Correlates, and Prognosis of Discrete Upper Septal Thickening on Echocardiography: The Framingham Heart Study | 0.9 | 74 | Citations (PDF) |
| 230 | In-Hospital and 1-Year Outcomes Among Percutaneous Coronary Intervention Patients With Chronic Kidney Disease in the Era of Drug-Eluting Stents | 3.0 | 149 | Citations (PDF) |
| 231 | Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart Study: Does the underlying health status play a role? | 1.5 | 60 | Citations (PDF) |
| 232 | Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study | 62.1 | 984 | Citations (PDF) |
| 233 | Predicting the 30-Year Risk of Cardiovascular Disease | 18.0 | 780 | Citations (PDF) |
| 234 | Cross-sectional relations of multiple biomarkers representing distinct biological pathways to plasma markers of collagen metabolism in the community | 2.1 | 10 | Citations (PDF) |
| 235 | Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond | 1.7 | 5,939 | Citations (PDF) |
| 236 | Comments on ‘Integrated discrimination and net reclassification improvements—Practical advice’ | 1.7 | 1,306 | Citations (PDF) |
| 237 | BMI vs. Waist Circumference for Identifying Vascular Risk | 4.0 | 67 | Citations (PDF) |
| 238 | Performance of a Method for Identifying the Unique Dietary Patterns of Adult Women and Men: The Framingham Nutrition Studies | 1.4 | 10 | Citations (PDF) |
| 239 | Association of Parental Hypertension With Concentrations of Select Biomarkers in Nonhypertensive Offspring | 6.6 | 23 | Citations (PDF) |
| 240 | Impact of Impaired Fasting Glucose on Cardiovascular Disease | 2.3 | 260 | Citations (PDF) |
| 241 | A Risk Score for Predicting Near-Term Incidence of Hypertension: The Framingham Heart Study | 9.6 | 271 | Citations (PDF) |
| 242 | General Cardiovascular Risk Profile for Use in Primary Care | 18.0 | 6,936 | Citations (PDF) |
| 243 | Aortic Root Diameter and Longitudinal Blood Pressure Tracking | 6.6 | 19 | Citations (PDF) |
| 244 | Embolic Protection and Platelet Inhibition During Renal Artery Stenting | 18.0 | 169 | Citations (PDF) |
| 245 | Long-Term Trends in the Incidence of Heart Failure After Myocardial Infarction | 18.0 | 497 | Citations (PDF) |
| 246 | Lifetime Risk of Cardiovascular Disease Among Individuals With and Without Diabetes Stratified by Obesity Status in the Framingham Heart Study | 6.2 | 216 | Citations (PDF) |
| 247 | Relations of Thyroid Function to Body Weight<subtitle>Cross-sectional and Longitudinal Observations in a Community-Based Sample</subtitle> | 8.1 | 282 | Citations (PDF) |
| 248 | C-Reactive Protein and Reclassification of Cardiovascular Risk in the Framingham Heart Study | 4.1 | 267 | Citations (PDF) |
| 249 | Vitamin D Deficiency and Risk of Cardiovascular Disease | 18.0 | 2,200 | Citations (PDF) |
| 250 | Advance Care Planning and Health Care Preferences of Community-Dwelling Elders: The Framingham Heart Study | 3.4 | 44 | Citations (PDF) |
| 251 | Interindividual variation in serum sodium and longitudinal blood pressure tracking in the Framingham Heart Study | 2.1 | 25 | Citations (PDF) |
| 252 | Temporal Trends in Self-Reported Functional Limitations and Physical Disability Among the Community-Dwelling Elderly Population: The Framingham Heart Study | 2.8 | 45 | Citations (PDF) |
| 253 | One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis | 16.5 | 1,265 | Citations (PDF) |
| 254 | Multimarker Approach to Evaluate the Incidence of the Metabolic Syndrome and Longitudinal Changes in Metabolic Risk Factors | 18.0 | 195 | Citations (PDF) |
| 255 | Increasing Cardiovascular Disease Burden Due to Diabetes Mellitus | 18.0 | 600 | Citations (PDF) |
| 256 | Clinical Utility of Different Lipid Measures for Prediction of Coronary Heart Disease in Men and Women | 16.5 | 526 | Citations (PDF) |
| 257 | Characteristics of Framingham Offspring Participants With Long-lived Parents | 8.1 | 56 | Citations (PDF) |
| 258 | Alcoholism and judgments of affective stimuli. | 1.6 | 58 | Citations (PDF) |
| 259 | Increasing Trends in Incidence of Overweight and Obesity over 5 Decades | 2.0 | 183 | Citations (PDF) |
| 260 | Lifetime Risk for Developing Dyslipidemia: The Framingham Offspring Study | 2.0 | 16 | Citations (PDF) |
| 261 | LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL management | 3.1 | 399 | Citations (PDF) |
| 262 | Genetic correlates of longevity and selected age-related phenotypes: a genome-wide association study in the Framingham Study | 1.8 | 178 | Citations (PDF) |
| 263 | Choice of time scale and its effect on significance of predictors in longitudinal studies | 1.7 | 168 | Citations (PDF) |
| 264 | Endogenous Sex Hormones and Cardiovascular Disease Incidence in Men | 9.6 | 198 | Citations (PDF) |
| 265 | Association of Parental Heart Failure with Risk of Heart Failure in Offspring | 34.5 | 184 | Citations (PDF) |
| 266 | Trends in the Incidence of Type 2 Diabetes Mellitus From the 1970s to the 1990s | 18.0 | 352 | Citations (PDF) |
| 267 | Estimating Lifetime Risk of Developing High Serum Total Cholesterol: Adjustment for Baseline Prevalence and Single-Occasion Measurements | 3.3 | 11 | Citations (PDF) |
| 268 | Electrocardiographic QRS Duration and the Risk of Congestive Heart Failure | 6.6 | 115 | Citations (PDF) |
| 269 | Estimated Risks for Developing Obesity in the Framingham Heart Study | 9.6 | 137 | Citations (PDF) |
| 270 | Cardiovascular Risk Factors Predictive for Survival and Morbidity-Free Survival in the Oldest-Old Framingham Heart Study Participants | 2.9 | 126 | Citations (PDF) |
| 271 | Unique Dietary Patterns and Chronic Disease Risk Profiles of Adult Men: The Framingham Nutrition Studies | 1.4 | 83 | Citations (PDF) |
| 272 | Sibling Cardiovascular Disease as a Risk Factor for Cardiovascular Disease in Middle-aged Adults | 16.5 | 224 | Citations (PDF) |
| 273 | Relations of Insulin Sensitivity to Longitudinal Blood Pressure Tracking | 18.0 | 54 | Citations (PDF) |
| 274 | C-Reactive Protein and Risk of Cardiovascular Disease in Men and Women From the Framingham Heart Study | 8.1 | 219 | Citations (PDF) |
| 275 | OverallC as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation | 1.7 | 1,378 | Citations (PDF) |
| 276 | Cross-sectional relations of urinary sodium excretion to cardiac structure and hypertrophyThe Framingham Heart Study | 2.0 | 5 | Citations (PDF) |
| 277 | Title is missing! | 2.0 | 14 | Citations (PDF) |
| 278 | Title is missing! 0 | | 1 | Citations (PDF) |
| 279 | Towards improving risk prediction through clustering analysis | 2.0 | 1 | Citations (PDF) |
| 280 | Automated Data Harmonization in Clinical Research: Natural Language Processing Approach | 1.2 | 3 | Citations (PDF) |
| 281 | Statin Eligibility According to Atherosclerotic Cardiovascular Disease Risk in the US | 11.1 | 6 | Citations (PDF) |
| 282 | Enabling inclusive systematic reviews: incorporating preprint articles with large language model-driven evaluations | 3.5 | 2 | Citations (PDF) |
| 283 | Overall Mortality and Comorbidities in Obstructive Sleep Apnea in Poland | 1.2 | 1 | Citations (PDF) |
| 284 | Beyond the Apnea–Hypopnea Index: Exploring Time-Dependent Hazard Ratios of Respiratory Events in Obstructive Sleep Apnea | 2.0 | 2 | Citations (PDF) |
| 285 | Pragmatic Approaches to the Evaluation and Monitoring of Artificial Intelligence in Health Care: A Science Advisory From the American Heart Association | 18.0 | 11 | Citations (PDF) |
| 286 | A federated learning framework for ethical dynamic treatment allocation across heterogeneous hospitals | 3.7 | 0 | Citations (PDF) |
| 287 | Performance of PREVENT Cardiovascular Risk in Electronic Health Record–Based Clinical Practice | 6.6 | 2 | Citations (PDF) |
| 288 | Cardiovascular Disease Risk and Noncardiovascular Chronic Disease Burden by Housing Status | 4.0 | 0 | Citations (PDF) |
| 289 | Rethinking cardiovascular prevention in the era of artificial intelligence | 2.0 | 0 | Citations (PDF) |
